玫瑰痤疮发病机制的研究进展

doi:10.35541/cjd.20230536

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (2): 186-190.doi: 10.35541/cjd.20230536

• 综述 • 上一篇

玫瑰痤疮发病机制的研究进展

刘亭微孟潇琦顾多多潘婼芯张悦许阳

南京医科大学第一附属医院皮肤科，南京 210029

收稿日期:2023-09-18 修回日期:2023-11-17 发布日期:2024-02-01
通讯作者: 许阳 E-mail:yangxu@njmu.edu.cn

Advances in the pathogenesis of rosacea

Liu Tingwei, Meng Xiaoqi, Gu Duoduo, Pan Ruoxin, Zhang Yue, Xu Yang

Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received:2023-09-18 Revised:2023-11-17 Published:2024-02-01
Contact: Xu Yang E-mail:yangxu@njmu.edu.cn

摘要/Abstract

摘要： 【摘要】玫瑰痤疮是一种面部慢性炎症性皮肤病，其发病主要与遗传、免疫、神经血管功能紊乱、微生物、皮肤屏障破坏、紫外线等因素密切相关，但其确切发病机制目前尚未完全明了，本文综述近5年相关机制研究进展。

关键词: 红斑痤疮, 发病机制, 病理生理学

Abstract: 【Abstract】 Rosacea is a chronic facial inflammatory skin disease. It has been proved that heredity, immunity, neurovascular disorders, microorganisms, skin barrier damage and ultraviolet rays are closely related to the occurrence of rosacea. However, the exact pathogenesis of rosacea has not been fully elucidated. This review summarizes recent advances in the pathogenesis of rosacea in the past 5 years.

Key words: Rosacea, Pathogenesis, Pathophysiology

刘亭微孟潇琦顾多多潘婼芯张悦许阳. 玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024,57(2):186-190. doi:10.35541/cjd.20230536

Liu Tingwei, Meng Xiaoqi, Gu Duoduo, Pan Ruoxin, Zhang Yue, Xu Yang. Advances in the pathogenesis of rosacea[J]. Chinese Journal of Dermatology, 2024, 57(2): 186-190.doi:10.35541/cjd.20230536

参考文献 48

［1］	van Zuuren EJ, Arents B, van der Linden M, et al. Rosacea: new concepts in classification and treatment［J］. Am J Clin Dermatol, 2021,22（4）:457⁃465. doi: 10.1007/s40257⁃021⁃00595⁃7.
［2］	Chang HC, Huang YC, Lien YJ, et al. Association of rosacea with depression and anxiety: a systematic review and meta⁃analysis［J］. J Affect Disord, 2022,299:239⁃245. doi: 10.1016/j.jad.2021. 12.008.
［3］	Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2018,179（2）:282⁃289. doi: 10.1111/bjd.16481.
［4］	Thiboutot D, Anderson R, Cook⁃Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2020,82（6）:1501⁃1510. doi: 10.1016/j.jaad.2020.01. 077.
［5］	Xiao W, Li J, Huang X, et al. Mediation roles of neutrophils and high⁃density lipoprotein （HDL） on the relationship between HLA⁃DQB1 and rosacea［J］. Ann Med, 2022,54（1）:1530⁃1537. doi: 10.1080/07853890.2022.2077427.
［6］	Deng Z, Chen M, Zhao Z, et al. Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea［J］. Nat Commun, 2023,14（1）:3958. doi: 10.1038/s41467⁃023⁃39761⁃2.
［7］	中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）［J］. 中华皮肤科杂志, 2021,54（4）:279⁃288. doi: 10.35541/cjd.20201078.
［8］	Zhang C, Kang Y, Zhang Z, et al. Long⁃term administration of LL⁃37 can induce irreversible rosacea⁃like lesion［J］. Curr Issues Mol Biol, 2023,45（4）:2703⁃2716. doi: 10.3390/cimb45040177.
［9］	Yoon SH, Hwang I, Lee E, et al. Antimicrobial peptide LL⁃37 drives rosacea⁃like skin inflammation in an NLRP3⁃dependent manner［J］. J Invest Dermatol, 2021,141（12）:2885⁃2894.e5. doi: 10.1016/j.jid.2021.02.745.
［10］	Deng Z, Chen M, Liu Y, et al. A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea［J］. EMBO Mol Med, 2021,13（5）:e13560. doi: 10.15252/emmm. 202013560.
［11］	Shih YH, Xu J, Kumar A, et al. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis［J］. J Invest Dermatol, 2020,140（5）:1100⁃1103.e4. doi: 10.1016/j.jid.2019.09.021.
［12］	Sun YH, Man XY, Xuan XY, et al. Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series［J］. Dermatol Ther, 2022,35（11）:e15848. doi: 10.1111/dth.15848.
［13］	Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea［J］. Front Med （Lausanne）, 2019,6:324. doi: 10.3389/fmed.2019.00324.
［14］	Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin⁃initiated skin inflammation in rosacea［J］. J Invest Dermatol, 2014,134（11）:2728⁃2736. doi: 10.1038/jid.2014.222.
［15］	Mascarenhas NL, Wang Z, Chang YL, et al. TRPV4 mediates mast cell activation in cathelicidin⁃induced rosacea inflammation［J］. J Invest Dermatol, 2017,137（4）:972⁃975. doi: 10.1016/j.jid.2016.10.046.
［16］	Al Hamwi G, Riedel YK, Clemens S, et al. MAS⁃related G protein⁃coupled receptors X （MRGPRX）: Orphan GPCRs with potential as targets for future drugs［J］. Pharmacol Ther, 2022,238:108259. doi: 10.1016/j.pharmthera.2022.108259.
［17］	Cao C, Kang HJ, Singh I, et al. Structure, function and pharmacology of human itch GPCRs［J］. Nature, 2021,600（7887）:170⁃175. doi: 10.1038/s41586⁃021⁃04126⁃6.
［18］	Zhou L, Zhao H, Zhao H, et al. GBP5 exacerbates rosacea⁃like skin inflammation by skewing macrophage polarization towards M1 phenotype through the NF⁃κB signalling pathway［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:796⁃809. doi: 10.1111/jdv.18725.
［19］	Liu Z, Zhang J, Jiang P, et al. Paeoniflorin inhibits the macrophage⁃related rosacea⁃like inflammatory reaction through the suppressor of cytokine signaling 3⁃apoptosis signal⁃regulating kinase 1⁃p38 pathway［J］. Medicine （Baltimore）, 2021,100（3）:e23986. doi: 10.1097/MD.0000000000023986.
［20］	Zhao Z, Liu T, Liang Y, et al. N2⁃polarized neutrophils reduce inflammation in rosacea by regulating vascular factors and proliferation of CD4+ T cells［J］. J Invest Dermatol, 2022,142（7）:1835⁃1844.e2. doi: 10.1016/j.jid.2021.12.009.
［21］	Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways［J］. J Invest Dermatol, 2015,135（9）:2198⁃2208. doi: 10.1038/jid.2015.141.
［22］	Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics［J］. Exp Dermatol, 2017,26（8）:659⁃667. doi: 10.1111/exd.13143.
［23］	Sinikumpu SP, Vähänikkilä H, Jokelainen J, et al. Male patients with rosacea have increased risk for migraine: a population⁃based study［J］. Br J Dermatol, 2021,185（5）:1058⁃1061. doi: 10.1111/bjd.20578.
［24］	Liu Y, Xu Y, Guo Z, et al. Identifying the neural basis for rosacea using positron emission tomography⁃computed tomography cerebral functional imaging analysis: a cross⁃sectional study［J］. Skin Res Technol, 2022,28（5）:708⁃713. doi: 10.1111/srt.13171.
［25］	刘乙萱, 姜沛彧,刘韵祎, 等. 玫瑰痤疮神经源性炎症及肉毒毒素治疗相关机制的研究进展［J］. 中华皮肤科杂志, 2022,55（6）:552⁃554. doi:10.35541/cjd.20200266.
［26］	Li M, Tao M, Zhang Y, et al. Neurogenic rosacea could be a small fiber neuropathy［J］. Front Pain Res （Lausanne）, 2023,4:1122134. doi: 10.3389/fpain.2023.1122134.
［27］	Choi JE, Di Nardo A. Skin neurogenic inflammation［J］. Semin Immunopathol, 2018,40（3）:249⁃259. doi: 10.1007/s00281⁃018⁃0675⁃z.
［28］	Kim HB, Na EY, Yun SJ, et al. The effect of capsaicin on neuroinflammatory mediators of rosacea［J］. Ann Dermatol, 2022,34（4）:261⁃269. doi: 10.5021/ad.21.223.
［29］	Marek⁃Jozefowicz L, Nedoszytko B, Grochocka M, et al. Molecular mechanisms of neurogenic inflammation of the skin［J］. Int J Mol Sci, 2023,24（5）:5001. doi: 10.3390/ijms2405 5001.
［30］	Jovanovic Z, Angabini N, Ehlen S, et al. Efficacy and tolerability of a cosmetic skin care product with trans⁃4⁃t⁃butylcyclohexanol and licochalcone A in subjects with sensitive skin prone to redness and rosacea［J］. J Drugs Dermatol, 2017,16（6）:605⁃610.
［31］	Kim HO, Kang SY, Kim KE, et al. Neurogenic rosacea in Korea［J］. J Dermatol, 2021,48（1）:49⁃55. doi: 10.1111/1346⁃8138. 15629.
［32］	Zhou X, Su Y, Wu S, et al. The temperature⁃sensitive receptors TRPV4 and TRPM8 have important roles in the pruritus of rosacea［J］. J Dermatol Sci, 2022,108（2）:68⁃76. doi: 10.1016/j.jdermsci.2022.11.004.
［33］	Liu T, Xiao W, Chen M, et al. Aberrant amino acid metabolism promotes neurovascular reactivity in rosacea［J］. JCI Insight, 2022,7（22）:e161870. doi: 10.1172/jci.insight.161870.
［34］	Kim J, Choi S, Choi S, et al. Contact hypersensitivity and Demodex mite infestation in patients with rosacea: a retro⁃spective cohort analysis［J］. Eur J Dermatol, 2022,32（6）:716⁃723. doi: 10.1684/ejd.2022.4358.
［35］	Lee SG, Kim J, Lee YI, et al. Cutaneous neurogenic inflammation mediated by TRPV1⁃NGF⁃TRKA pathway activation in rosacea is exacerbated by the presence of Demodex mites［J］. J Eur Acad Dermatol Venereol, 2023,37（12）:2589⁃2600. doi: 10.1111/jdv. 19449.
［36］	Zaidi AK, Spaunhurst K, Sprockett D, et al. Characterization of the facial microbiome in twins discordant for rosacea［J］. Exp Dermatol, 2018,27（3）:295⁃298. doi: 10.1111/exd.13491.
［37］	Rainer BM, Thompson KG, Antonescu C, et al. Characterization and analysis of the skin microbiota in rosacea: a case⁃control study［J］. Am J Clin Dermatol, 2020,21（1）:139⁃147. doi: 10. 1007/s40257⁃019⁃00471⁃5.
［38］	Zhang Y, Zhou Y, Humbert P, et al. Effect on the skin microbiota of oral minocycline for rosacea［J］. Acta Derm Venereol, 2023,103:adv10331. doi: 10.2340/actadv.v103.10331.
［39］	Mahmud MR, Akter S, Tamanna SK, et al. Impact of gut microbiome on skin health: gut⁃skin axis observed through the lenses of therapeutics and skin diseases［J］. Gut Microbes, 2022,14（1）:2096995. doi: 10.1080/19490976.2022.2096995.
［40］	Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut⁃skin axis［J］. Clin Dermatol, 2021,39（5）:829⁃839. doi: 10.1016/j.clindermatol.2021.08.021.
［41］	Baldwin H, Alexis AF, Andriessen A, et al. Evidence of barrier deficiency in rosacea and the importance of integrating OTC skincare products into treatment regimens［J］. J Drugs Dermatol, 2021,20（4）:384⁃392. doi: 10.36849/JDD.2021.5861.
［42］	Medgyesi B, Dajnoki Z, Béke G, et al. Rosacea is characterized by a profoundly diminished skin barrier［J］. J Invest Dermatol, 2020,140（10）:1938⁃1950.e5. doi: 10.1016/j.jid.2020.02.025.
［43］	Passeron T, Zouboulis CC, Tan J, et al. Adult skin acute stress responses to short⁃term environmental and internal aggression from exposome factors［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:1963⁃1975. doi: 10.1111/jdv.17432.
［44］	Deng Z, Chen M, Xie H, et al. Claudin reduction may relate to an impaired skin barrier in rosacea［J］. J Dermatol, 2019,46（4）:314⁃321. doi: 10.1111/1346⁃8138.14792.
［45］	Wang Y, Wang B, Huang Y, et al. Multi⁃transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of rosacea［J］. J Inflamm Res, 2022,15:2141⁃2156. doi: 10.2147/JIR.S356551.
［46］	Suhng E, Kim BH, Choi YW, et al. Increased expression of IL⁃33 in rosacea skin and UVB⁃irradiated and LL⁃37⁃treated HaCaT cells［J］. Exp Dermatol, 2018,27（9）:1023⁃1029. doi: 10.1111/exd.13702.
［47］	Kulkarni NN, Takahashi T, Sanford JA, et al. Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression［J］. J Invest Dermatol, 2020,140（3）:645⁃655.e6. doi: 10.1016/j.jid.2019.08.436.
［48］	Sun Y, Chen L, Wang H, et al. Activation of aryl hydrocarbon receptor ameliorates rosacea⁃like eruptions in mice and suppresses the TLR signaling pathway in LL⁃37⁃induced HaCaT cells［J］. Toxicol Appl Pharmacol, 2022,451:116189. doi: 10. 1016/j.taap.2022.116189.

[1]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[2]	张悦陶梦李敏姜沛彧刘韵祎刘乙萱潘婼芯许阳. 玫瑰痤疮病情评价标准研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 182-185.
[3]	潘婼芯顾多多张悦李敏陶梦许阳. 代谢组学在玫瑰痤疮研究中的应用进展[J]. 中华皮肤科杂志, 2024, 57(2): 178-181.
[4]	魏子妤杨勇. 离子通道与玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 174-177.
[5]	李吉谢红付. 如何避免玫瑰痤疮的误诊[J]. 中华皮肤科杂志, 2024, 57(2): 119-122.
[6]	蒋献宋德宇. [开放获取] 从心身医学视角认识玫瑰痤疮[J]. 中华皮肤科杂志, 2024, 57(2): 123-126.
[7]	那君李若瑜仲少敏杨莉吴艳. 玫瑰痤疮真实世界诊疗现状调查分析[J]. 中华皮肤科杂志, 2024, 57(2): 127-133.
[8]	马光荣谢红付刘家双周钟莲周淞麒黄莹雪李吉. 玫瑰痤疮患者小肠细菌过度生长情况调查及临床特征分析[J]. 中华皮肤科杂志, 2024, 57(2): 134-140.
[9]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[10]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[11]	陶梦李敏刘乙萱刘韵祎姜沛彧张嘉文南宇晴许阳. 玫瑰痤疮与精神神经性疾病相关性研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 693-697.
[12]	米淑宏余艳琴郝金奇李薇张杨贾喜梅黄毓娴孙怀玉石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544.
[13]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[14]	李容张家安陈崑. 玫瑰痤疮光电疗法研究进展[J]. 中华皮肤科杂志, 2023, 56(5): 468-470.
[15]	李嘉祺叶枫鞠强. 表皮葡萄球菌共生性稳态与皮肤疾病[J]. 中华皮肤科杂志, 2023, 56(5): 459-462.

玫瑰痤疮发病机制的研究进展

Advances in the pathogenesis of rosacea

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

Metrics

本文评价

推荐阅读 10